Stock Movers: Eli Lilly's Drug Sales Surge, Comcast Subscriber Losses Slow, Meta's AI Spending Concerns

Eli Lilly's Strong Performance

• 📈 Eli Lilly saw its stock jump significantly following a raised full-year guidance, driven by strong sales from its weight loss and diabetes drugs.
• 💊 The company's diabetes drug Mounjaro and obesity treatment Zepbound exceeded expectations by nearly $1.3 billion, with the diabetes drug accounting for the majority of the beat.
• 🏆 Eli Lilly now holds 58% market share in the weight loss drug market, directly competing with Novo Nordisk's Ozempic and Wegovy, and is seen as clearly winning this race.

Comcast's Subscriber Numbers

• 📉 Comcast reported a mixed earnings report, losing 104,000 net broadband subscribers, which was fewer than the 140,000 analysts predicted.
• 📺 The company also lost 257,000 video subscribers, beating expectations for 321,000 departures.
• 📊 Despite these numbers, revenue fell 2.7% to $31.2 billion, though this still beat estimates of $30.7 billion. This marks the 10th consecutive quarter of domestic broadband customer losses.

Meta's AI Investment and Market Reaction

• 💰 Meta Platforms aims to sell at least $25 billion of investment-grade bonds to fund its aggressive artificial intelligence spending.
• 🌐 The company needs to invest billions in data centers and infrastructure to support its AI services integrated into key products.
• 📉 The stock fell nearly 12%, with earlier trading seeing a 14% drop, stemming from concerns over the substantial AI investment outlook.
• ⏳ Analysts suggest investors may struggle to rationalize Meta's current stock prices until at least 2027 due to these high spending requirements.